Phaseline

Companies › Clarion Cells

Clarion Cells: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Aug 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NR1
Human embryonic stem cell (hESC) derived neural stem cells for tissue repair and regenerat
–Phase 1Ischemic StrokeAug 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04631406NR1Phase 1Ischemic StrokeNeurologyAug 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.